Last reviewed · How we verify
V920
At a glance
| Generic name | V920 |
|---|---|
| Also known as | BPSC-1001 |
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- African-Canadian Study of HIV-Infected Adults and a Vaccine for Ebola - ACHIV-Ebola (PHASE2)
- Partnership for Research on Ebola VACcinations (PHASE2)
- Safety and Immunogenicity of the rVSVΔG-ZEBOV-GP Ebola Virus Vaccine Candidate in Children Living in Lambaréné, Gabon (PHASE1, PHASE2)
- Placebo Controlled, Dose Response, Safety and Immunogenicity Study of Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-004) (PHASE1)
- Vaccine Treatment for Ebola Virus in Healthy Adults (V920-001) (PHASE1)
- Safety and Immunogenicity of Prime-Boost Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-002) (PHASE1)
- Evaluation of the Safety and Immunogenicity of Three Consistency Lots and a High-Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults (V920-012) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- V920 CI brief — competitive landscape report
- V920 updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI